Alvenor Tablet

Diosmin and Hesperidin is a phlebotonic drug and a vascular protecting agent. It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus Diosmin and Hesperidin decreases venous capacitance, venous distensibility, and venous emptying time.

Diosmin and Hesperidin protects the microcirculation by fighting the microcirculation damaging process; It combats venous inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandin. Thus Diosmin and Hesperidin normalizes capillary permeability and strengthens capillary resistance. 

Diosmin and Hesperidin acts on the lymphatic system, It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure.


It is used for the treatment of venous disease, ie. chronic venous disaese & hemorrhoidal disease.

Trade Name Alvenor
Generic Micronised Diosmin + Hesperidin
Weight 450mg+50mg
Type Tablet
Therapeutic Class Phlebotonic & Vascular protecting preparation
Manufacturer Beacon Pharmaceuticals Ltd
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:23 am


Alvenor dosage


  • Acute attack: 6 tablets daily for the 1st 4 days followed by 4 tablets daily for the next 3 days.
  • Chronic haemorrhoids: 2 tablets daily.

Chronic venous disease: 2 tablets daily. The tablets should be taken at meal times.

Side Effects

Possible side-effects are cutaneous allergies, gastrointestinal disorders, headaches and flushes.


Acute hemorrhoidal attack: If the hemorrhoid symptoms do not disappear within 15 days, the patient should ask the doctor for advice. Venous circulation disorders: The most effective way of giving this treatment is in combination with a healthy lifestyle. Avoid exposure to the sun, heat, excessive standing and being overweight. Walking and wearing special support stockings stimulate blood circulation.

Pregnancy & Breastfeeding use

Pregnancy: There were no teratogenic observations in human studies. It is, however, recommended that it should not be administered during the first three months of pregnancy.

Lactation: In the absence of data concerning the diffusion of the drug substance in the breast milk, breast feeding is not recommended during treatment.


It is contra-indicated in patients, who have shown hypersensitivity to any of the substances present in the drug.

Acute Overdose

No overdosage symptoms have been observed.

Storage Condition

Store at a cool & dry place, protect from light & moisture.